Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?

Journal: BMJ open diabetes research & care
PMID: 32043472

Abstract

OBJECTIVE: This study evaluated the characteristics of new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) in clinical practice to assess the applicability of the findings from clinical trials (Empagliflozin, Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial, Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 trial, Canagliflozin Cardiovascular Assessment Study (CANVAS) program and the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS-CV) trial) and multinational observational studies (CVD-REAL Nordic study and CVD-REAL 2 study).

Authors

  • Shih-Chieh Shao
    Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Yi-Han Lin
    Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Kai-Cheng Chang
    Department of Pharmacy, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Yuk-Ying Chan
    Department of Pharmaceutical Materials Management, Chang Gung Medical Foundation, Taoyuan, Taiwan.
  • Ming-Jui Hung
    Division of Cardiology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Yea-Huei Kao Yang
    School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Edward Chia-Cheng Lai
    School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan edward_lai@mail.ncku.edu.tw.

Keywords

External Resources

Popular Topics
Recent Journals